A national FINGUS study assessed guselkumab treatment patterns and outcomes in Finnish adult patients with plaque psoriasis. The study was carried out in 15 Finnish treatment centres specialising in the care of plaque psoriasis. All the adult patients starting guselkumab treatment in the centres between Dec 1st 2017 and Dec 1st 2019 were included in the study. The data consist of the patient records of 181 adults and the data were collected retrospectively.
The main objectives were to investigate the clinical outcomes at 9-14 months of treatment and to explore the persistence of treatment. The study also assessed dosing patterns, the reasons of treatment discontinuation, as well as short- and long-term clinical outcomes.
The results were positive regarding both main objectives. The symptoms of 80% of the patients were eased and their PASI (Psoriasis Area and Severity Index) score was 2 or below at 9-14 months after treatment initiation. 86% of the patients were on guselkumab treatment at one year.
Based on this study, guselkumab is effective treatment of plaque psoriasis in Finland and treatment persistence is high.
Mälkönen T, Nuutinen P, Hallinen T, Soini E, et al. Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Derm Venereol 2022; 102: adv00631.